Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2- metastatic breast cancer.
Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2- metastatic breast cancer.
复制标题
激素受体/HER2-转移性乳腺癌中哌柏西利耐药性的前瞻性纵向多组学研究。
DOI：
10.1200/jco.2021.39.15_suppl.1013
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Zhengyan Kan
中科院分区：
文献类型：
--
作者：
Yeon;S. Im;Kyunghee Park;J. Wen;A. Min;V. Bonato;Seri Park;S. Ram;Dae;Ji;Kyung;Won;Jisook Lee;Hyunseon Kim;W. Lee;Yoon;S. Weinrich;H. Ryu;W. Park;Zhengyan Kan
背景：CDK 4/6抑制剂的开发代表了转移性乳腺癌（MBC）治疗的重大进展。为了更好地了解治疗和耐药性的影响...
1013Background: The development of CDK4/6 inhibitors represents a significant advance in the treatment of metastatic breast cancer (MBC). To better understand the impact of treatment and drug resis...